Results 51 to 60 of about 1,026 (172)

Bridging the Diagnostic Gap in Chronic Hepatitis D: Implementing Reflex Testing and Standardized HDV RNA Assessment in the Therapeutic Era

Liver International Communications, Volume 7, Issue 3, September 2026.
ABSTRACT Chronic hepatitis D virus (HDV) infection is the most severe form of viral hepatitis, yet it remains frequently underdiagnosed in routine clinical practice. With the recent availability of effective therapies such as bulevirtide, missed or delayed diagnosis has become an increasingly relevant clinical issue.
Francesco De Maria, Nadia Marascio, Paolo Fusco, Maria Teresa Tassone, Chiara Costa, Angela Quirino, Giovanni Matera, Alessandro Russo   +7 more
wiley   +1 more source

Dynamics of Virological and Clinical Response Parameters of Bulevirtide Treatment for Hepatitis D: Real-World Data

Gastro Hep Advances
Background and Aims: The entry inhibitor bulevirtide represents the first specific treatment for hepatitis-D virus (HDV)-infected patients. In clinical trials, around 80% of patients achieve normalization of alanine aminotransferase (ALT) with about 60 ...
Alexander Killer, Smaranda Gliga, Carolin Lohr, Christian Weigel, Björn-Erik Ole Jensen, Nadine Lübke, Andreas Walker, Jörg Timm, Johannes Bode, Tom Luedde, Hans H. Bock   +10 more
doaj   +1 more source

BREAKTHROUGH ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS D

Актуальные проблемы теоретической и клинической медицины
For a long period of 46 years since the discovery of the hepatitis D virus antigen by M. Rizzetto in 1977, chronic hepatitis D was considered in conjunction with chronic hepatitis B, classified as chronic hepatitis B with the delta agent.
D. I. Otunbayeva, B. K. Nurgalieva, S. S. Kariyeva   +2 more
doaj   +1 more source

Bulevirtide‐based treatment strategies for chronic hepatitis delta: A review

Journal of Viral Hepatitis, 2023
AbstractChronic hepatitis Delta (CHD) is a rare and severe form of chronic viral hepatitis. Until recently, the only therapeutic approach has been the off‐label use of a 48 weeks course of PegInterferon alpha (PegIFNα), that was characterized by suboptimal efficacy and burdened by significant side effects that limited treatment applicability in ...
Elisabetta Degasperi, Maria Paola Anolli, Pietro Lampertico   +2 more
openaire   +2 more sources

Geospatial Discrepancy of Chronic Hepatitis B and Hepatitis D Testing in Alberta: A Population‐Based Spatial Analysis

Journal of Viral Hepatitis, Volume 33, Issue 9, September 2026.
ABSTRACT Chronic hepatitis B (CHB) and hepatitis D virus (HDV) coinfection are major causes of cirrhosis and hepatocellular carcinoma. The geographic distribution of CHB and alignment of anti‐HDV testing with CHB burden remain poorly defined. We aimed to examine if anti‐HDV testing and seropositivity align with areas of highest CHB burden.
Bryce Tkachuk, Isabelle Couloigner, Carla S. Coffin, Jason Jiang, Stefania Bertazzon, Abdel‐Aziz Shaheen   +5 more
wiley   +1 more source

Pharmacotherapy of hepatitis D: the current and the future [PDF]

Exploration of Digestive Diseases
Hepatitis D virus (HDV), a satellite virus requiring hepatitis B surface antigen (HBsAg) for propagation, is a hepatotropic virus implicated in acute and chronic viral hepatitis, with an accentuated risk of cirrhosis and hepatocellular carcinoma.
George Sarin Zacharia, Anu Jacob
doaj   +1 more source

From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatitis delta virus (HDV) infection causes chronic hepatitis D (CHD), the most severe form of chronic viral hepatitis with a high risk of progression to advanced liver disease. Off‐label pegylated interferon alpha was the primary treatment option in Europe prior to the introduction of bulevirtide, a first‐in‐class HDV entry inhibitor.
Monica Radu, Margarita Papatheodoridi, Habiba Kamal Khodir, Sabela Lens, Elisabetta Degasperi, Speranta Iacob, Liliana Gheorghe, Katja Steppich, Florin Alexandru Caruntu, Pietro Lampertico, Soo Aleman, Heiner Wedemeyer   +11 more
wiley   +1 more source

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?

Current Issues in Molecular Biology, 2023
Chronic delta hepatitis is a global health problem. Although a smaller percentage of chronic HBV-infected patients are coinfected with the hepatitis delta virus, these patients have a higher risk of an accelerated progression to fulminant “delta ...
Roxana Nemteanu, Andreea Clim, Corina Elena Hincu, Liliana Gheorghe, Irina Ciortescu, Alina Plesa   +5 more
doaj   +1 more source

Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 2, Page 196-207, July 2026.
Bulevirtide increases bile acid levels in most patients; however, changes in bile acids do not predict virological response or adverse events, nor do they reflect treatment adherence. After discontinuation of bulevirtide, bile acid levels rapidly decline.
Marlene Hintersteininger, Michael Schwarz, Philipp Schwabl, Lukas Hartl, Lorenz Balcar, Benedikt Silvester Hofer, Georg Kramer, Christian Sebesta, Paul Thöne, Patrik Attalla, Michael Gschwantler, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Mathias Jachs   +14 more
wiley   +1 more source

Current and future therapeutic options for chronic hepatitis D virus infection

Frontiers in Cellular and Infection Microbiology
In the last few years there have been innovations in HDV therapy which have brought new excitement in the scientific community also considering the few therapeutic opportunities.
Mariantonietta Pisaturo, Antonio Russo, Pierantonio Grimaldi, Salvatore Martini, Nicola Coppola   +4 more
doaj   +1 more source